Teva Pharmaceuticals
TEVA
550 hedge funds and large institutions have $13.3B invested in Teva Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 74 funds opening new positions, 185 increasing their positions, 180 reducing their positions, and 61 closing their positions.
71% more call options, than puts
Call options by funds: $730M | Put options by funds: $428M
21% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 61
17% more funds holding in top 10
Funds holding in top 10: 23 → 27 (+4)
11% more capital invested
Capital invested by funds: $11.9B → $13.3B (+$1.32B)
2% more funds holding
Funds holding: 539 → 550 (+11)
3% more repeat investments, than reductions
Existing positions increased: 185 | Existing positions reduced: 180
5.56% less ownership
Funds ownership: 62.86% → 57.3% (-5.6%)
Top Buyers
Top Sellers
TEVA Hedge Fund Activity: Q3 2025 in Review
550 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2025, worth a combined $13.3B — up 11% from $11.9B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new TEVA positions and 61 closed out — a net gain of 13 holders — while 185 added to existing stakes and 180 trimmed.
The largest buyer was Altshuler Shaham, adding an estimated $131M. The largest seller was Fidelity Investments, cutting an estimated $588M.
- 550 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2025, up from 539 in Q2 2025.
- Funds reported $13.3B of Teva Pharmaceuticals stock for Q3 2025, up 11% quarter-over-quarter.
- 74 funds opened new Teva Pharmaceuticals positions in Q3 2025 and 61 closed out, a net change of +13 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2025 was Altshuler Shaham, an estimated $131M added.
- The largest Teva Pharmaceuticals seller in Q3 2025 was Fidelity Investments, an estimated $588M sold.
Based on aggregated 13F filings for Q3 2025.